Dr. Nathan R. Hill D.Phil(oxon.) σξ
About Dr. Nathan R. Hill D.Phil(oxon.) σξ
Dr. Nathan R. Hill is the Director of Real World Evidence Strategy at Bristol Myers Squibb in London, with over twenty years of experience in the medical industry and a background in epidemiology, health economics, and medical mathematics.
Company
Dr. Nathan R. Hill currently works at Bristol Myers Squibb in London, England, United Kingdom. He holds the position of Director for Real World Evidence Strategy within the Worldwide Health Economics and Outcomes Research (WW HEOR) division. His tenure with Bristol Myers Squibb includes prior roles such as Associate Director - RWE and Advanced Analytic Lead - Market Access, Regional Access Manager, and Outcomes Research Scientist (RWE) - Medical Affairs.
Title
Dr. Hill serves as the Director of Real World Evidence Strategy at Bristol Myers Squibb. His role involves the strategic delivery of pharmaceutical access and real-world evidence research, underlining his expertise in AI applications within the medical field.
Education and Expertise
Dr. Hill holds a DPhil in Medical Mathematics from the University of Oxford, a Master's degree in Epidemiology from the London School of Hygiene and Tropical Medicine, a pgCert in Health Economics from the University of York, and a BSc(Hons.) in Software Engineering from Sheffield Hallam University. His academic journey contributes to his specialization in epidemiology, real-world evidence, and pharmaceutical access strategy.
Background
Dr. Hill has over twenty years of experience in the medical industry, with significant roles at the University of Oxford, where he served as a Senior Research Fellow and Beta-cell Modelling Lead in Diabetes. His diverse career also includes roles such as IT Manager at Oxfordshire Primary Care Trust, COO at eMediaTrack, and Director at Within Computing Ltd. In academia, he has been an Executive Board Member and the Secretary of the Society for Academic Primary Care.
Achievements
Dr. Hill has authored over 100 publications in epidemiology and real-world evidence. He led the award-winning 'Machine Learning for Atrial Fibrillation Detection' project and developed the 'Body of Evidence approach,' both recognized by BMS Global Innovation awards. Additionally, he co-founded the Oxford Research Society and won the BMS Commercial Grand Champion Innovation award in 2021.